Genelux (GNLX) Consolidated Net Income (2022 - 2026)

Genelux's (GNLX) quarterly Consolidated Net Income came in at -$9.3 million in Q1 2026, down 21.02% year-on-year from -$11.8 million in Q1 2025, and up 89.37% quarter-over-quarter from -$87.8 million in Q4 2025.

Genelux (GNLX) Consolidated Net Income (2022 - 2026) Analysis & Trends

Genelux's Consolidated Net Income history runs 5 years deep, the most recent figure standing at -$9.3 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 21.02% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$116.5 million, a 278.33% decrease from a year earlier, with the FY2025 full-year figure at -$111.0 million, down 21.05% from the prior year.
  • Consolidated Net Income grew to -$9.3 million in Q1 2026 per GNLX's latest filing, from -$87.8 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $4.9 million in Q3 2022 and bottomed at -$117.2 million in Q2 2023.
  • The 5-year median for Consolidated Net Income is -$8.1 million (2025), against an average of -$19.6 million.
  • Across the five-year window, Consolidated Net Income surged 94.26% in 2024 and sank 828.27% in 2025, its largest moves.
  • Year by year, Consolidated Net Income stood at -$3.5 million in 2022, then sank by 93.62% to -$6.8 million in 2023, then tumbled by 39.78% to -$9.5 million in 2024, then sank by 828.27% to -$87.8 million in 2025, then soared by 89.37% to -$9.3 million in 2026.
  • Per Business Quant, the three latest GNLX Consolidated Net Income figures stand at -$9.3 million (Q1 2026), -$87.8 million (Q4 2025), and -$11.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Oculis Holding AG 65,839.48 Bn 65,839.20 Bn - -37.09 Mn
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,015.37 Bn 1,015.37 Bn - -14.46 Mn
4 BeOne Medicines 471.39 Bn 466.59 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 122.52 Bn 115.28 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 70.33 Bn 61.58 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.74 Bn 62.74 Bn - -26.94 Mn
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn 362.00 Mn
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn 205.99 Mn
10 Genelux 128.92 Mn 128.92 Mn - -9.33 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.33 Mn
Dec 31, 2025 -87.81 Mn
Sep 30, 2025 -11.28 Mn
Jun 30, 2025 -8.06 Mn
Mar 31, 2025 -7.71 Mn
Dec 31, 2024 -9.46 Mn
Sep 30, 2024 -6.89 Mn
Jun 30, 2024 -6.73 Mn
Mar 31, 2024 -9.50 Mn
Dec 31, 2023 -6.77 Mn
Sep 30, 2023 -5.35 Mn
Jun 30, 2023 -117.16 Mn
Mar 31, 2023 -9.57 Mn
Dec 31, 2022 -3.50 Mn
Sep 30, 2022 4.91 Mn